Collectively, considering the relevance of Ca2+ dyshomeostasis in neurodegeneration, the validation of new drugs toward STIM1 targets may result in successful treatment strategies for AD, PD, HD, ALS and stroke. This evidence concerns the gene STIM1 and stroke disorder.